Skip to main content
. 2022 Jul 14;77(2):558–572. doi: 10.1002/hep.32620

FIGURE 4.

FIGURE 4

Plasma triggering receptor expressed on myeloid cell 2 (TREM2) levels can identify patients with NASH from subjects with NAFLD activity score (NAS) <4 in a large validation study (n = 170). Study 1, patients with severe obesity; Study 2, patients with type 2 diabetes; and Study 3, patients screened for liver disease. (A) Quantitative enzyme‐linked immunosorbent assay analysis of TREM2 levels in plasma extracted from patients with NAS ≥4 and subjects with NAS <4 categorized according to NAS. (B) Diagnostic accuracy of plasma TREM2 levels in patients with NAS ≥4 and subjects with NAS <4. (C) Plasma TREM2 levels according to NAFLD activity score (0–8) with dual cutoff rule‐in NAS ≥4 (≥65 ng/ml) and rule‐out NAS <4 (≤38 ng/ml) patients and diagnostic accuracy test probabilities for plasma TREM2 with 95% confidence intervals for NAS ≥4 (at‐risk NASH), with 2 × 2 tables. LR+, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value. (D) Diagnostic accuracy of plasma TREM2 across different validation cohorts.